Nanotechnology-Driven Innovations in Malaria Treatment and Control: Current Challenges and Pharmaceutical Strategies

Shaik Harun Rasheed, Kondapuram Parameshwar*, K. Mallikarjuna Reddy,

G. Sushmitha, Sesha Madhavi M.

Faculty of Pharmacy, Gurunanak Institutions Technical Campus - School of Pharmacy,

Hyderabad - 501506, Telangana, India.

*Corresponding Author E-mail: parameshwarkp@gmail.com

ABSTRACT:

In the ongoing fight against malaria, an age-old disease responsible for hundreds of thousands of deaths annually, advancements in nanotechnology present new horizons for innovative interventions. This review provides a comprehensive review of the current state of nanotechnology-driven solutions in malaria treatment and control, outlining the ground-breaking opportunities they present and their challenges. Nanoparticle-based drug delivery systems have shown enhanced therapeutic efficacy, targeted delivery, and reduced side effects. Similarly, nanotechnology has paved the way for improved diagnostic tools with higher sensitivity and rapid detection capabilities. Furthermore, nano-enhanced vector control strategies have emerged, aiming to tackle malaria transmission at its source. Despite these advancements, challenges such as scale-up, biosafety, environmental concerns, and cost considerations persist. By bridging the gap between current challenges and pharmaceutical strategies, this review sheds light on the future direction of nanotechnology in malaria eradication, underscoring the potential it holds for revolutionizing the field and bringing us closer to a malaria-free world.

KEYWORDS: Nanotechnology, Malaria Treatment, Drug Delivery, Diagnosis, Vector Control, Challenges, Pharmaceutical Strategies.

INTRODUCTION:

Malaria, a mosquito-borne infectious disease caused by Plasmodium parasites, threatens global public health substantially.¹ Despite significant progress in controlling the disease over the past few decades, malaria remains a major cause of morbidity and mortality, particularly in tropical and subtropical regions.² The development of drug-resistant malaria parasites, challenges in vector control, and the lack of effective vaccines have underscored the urgent need for innovative approaches to tackle this persistent problem.³

The burden of malaria is staggering, with hundreds of millions of cases and hundreds of thousands of deaths reported annually. The disease disproportionately affects vulnerable populations, including children under five and pregnant women.⁴ Malaria also exerts a considerable economic toll on endemic countries, hindering development and perpetuating the cycle of poverty.⁵

The emergence of drug-resistant Plasmodium strains, commonly used antimalarial drugs such as chloroquine and sulfadoxine-pyrimethamine, has further complicated treatment efforts.⁶ This backdrop of challenges has spurred research into novel malaria treatment and control strategies. Nanotechnology's potential to revolutionize drug delivery, diagnostics, and vaccine development has emerged as a promising avenue for addressing the limitations of conventional interventions.⁷

This review article aims to explore nanotechnology-driven innovations in malaria treatment and control comprehensively. It delves into the various facets of nanotechnology's application, including drug delivery systems, antimalarial nanoformulations, nano vaccines, and nano diagnostic tools. The review discusses the opportunities and challenges of integrating nanotechnology into malaria management strategies, highlighting its potential to overcome existing limitations.⁸

Malaria Epidemiology and Impact:

Malaria remains a formidable global health challenge, particularly in regions with high transmission rates and limited healthcare resources.⁹ The disease is caused by Plasmodium parasites, with Plasmodium falciparum being the deadliest species. Malaria transmission occurs predominantly through the bite of infected Anopheles mosquitoes.¹⁰ The burden of malaria is concentrated in sub-Saharan Africa, Southeast Asia, and parts of South America, where climate, geography, and socioeconomic factors create conducive conditions for transmission.¹¹

The impact of malaria on human health is staggering. Despite efforts to reduce its prevalence, hundreds of millions of cases are reported annually, leading to many deaths, mostly among children and pregnant women.¹² Malaria-related mortality contributes significantly to global mortality rates, particularly in children under five.¹³ Furthermore, the disease perpetuates a cycle of poverty, hindering economic development in affected regions (Figure.1).

Fig. 1: Life cycle of malaria parasite

Current Treatment Approaches:

Antimalarial drugs such as chloroquine, quinine, Mefloquine, Primaquine, Atovaquone and artemisinin-based combination therapies (ACTs) have been the mainstay of malaria treatment. ACTs have proven effective in managing uncomplicated malaria cases. However, the emergence of drug-resistant Plasmodium strains has compromised the effectiveness of these treatments. Necessitated the constant adaptation of treatment regimens and the development of new drugs to counteract drug resistance.¹⁴

In addition to drug-based interventions, vector control measures such as insecticide-treated bed nets and indoor residual spraying are crucial in reducing malaria transmission. These strategies target the Anopheles mosquitoes responsible for transmitting the parasites. However, insecticide resistance and sustainable implementation pose ongoing hurdles to achieving consistent control. (Figure 2)

Figure 2: Chemical structures of anti-malarial agents

Chloroquine:

Chloroquine is an antimalarial drug that has historically been widely used to treat and prevent malaria. It was once highly effective against Plasmodium falciparum, a malaria parasite responsible for severe disease.

Chloroquine exerts its antimalarial effects by interfering with the parasite's ability to digest haemoglobin within infected red blood cells. It accumulates within the parasite's food vacuole, disrupting its digestive processes and leading to the toxic buildup and other metabolic waste. Ultimately results in the death of the parasite. The extensive and widespread use of chloroquine led to the development drug-resistant strains of Plasmodium falciparum in many regions. While chloroquine's use has declined due to resistance, it still finds some application in areas where Plasmodium parasites remain sensitive to the drug. In some instances, chloroquine is still prescribed for treating malaria caused by less virulent species, such as Plasmodium vivax and malaria, in regions where resistance is not a significant concern.¹⁵

Quinine:

Quinine is an antimalarial drug derived from the bark of the Cinchona tree and has been used for centuries as a treatment for malaria. It played a vital role in combating malaria before developing modern antimalarial drugs. Quinine's antimalarial effects stem from interfering with the malaria parasite's ability to digest haemoglobin within infected red blood cells. By accumulating within the parasite's food vacuole, quinine disrupts its metabolic processes and leads to the buildup of toxic byproducts. Ultimately results in the death of the parasite. Combining quinine with other antimalarial drugs, such as clindamycin, has improved treatment outcomes. These combination therapies can enhance the antimalarial effects and reduce the duration of hospital stays.¹⁶

Mefloquine:

Mefloquine is an antimalarial drug in the class of medications known as quinolines. It has been used to treat and prevent malaria, particularly in regions where drug resistance is a concern. Mefloquine is an antimalarial drug in the class of medications known as quinolines. It has been used to treat and prevent malaria, particularly in regions where drug resistance is a concern. Mefloquine was initially introduced as a treatment for chloroquine-resistant strains of Plasmodium falciparum, which had become widespread in various parts of the world. It was used as an alternative to other antimalarial drugs when resistance to those drugs was observed.¹⁷

Primaquine:

Primaquine is an antimalarial medication used to treat and prevent certain types of malaria infections. It is particularly effective against the dormant liver stage of the Plasmodium parasite, making it valuable for preventing malaria relapses caused by Plasmodium vivax and Plasmodium. Primaquine's primary mechanism of action involves targeting the dormant liver stages (hypnozoites) of Plasmodium parasites that can lead to malaria relapses. It disrupts the metabolic processes within these stages, preventing their development into the active blood-stage parasites that cause clinical symptoms. Primaquine is used to avoid malaria relapses caused by Plasmodium vivax and Plasmodium. These species have a dormant liver stage that can reactivate and cause recurrent infections. Primaquine effectively clears these dormant stages, reducing the risk of relapse.¹⁸

Atovaquone:

Atovaquone is an antimalarial medication used as part of combination therapies to treat malaria. It is commonly combined with proguanil to create the drug combination atovaquone/proguanil, also known as Malarone. Targets the electron transport chain within the mitochondria of the malaria parasite, disrupting the parasite's ability to generate energy (ATP). This disruption impairs the parasite's metabolic processes and ultimately leads to its death. Atovaquone/proguanil is a prophylactic (preventive) treatment for individuals traveling to malaria-endemic regions. When taken as prescribed before, during, and after travel, it offers protection against malaria infection.¹⁹

Artemisinin-based combination therapies (ACTs):

Artemisinin-based combination therapies (ACTs) are a class of antimalarial treatments that combine an artemisinin derivative with one or more other antimalarial drugs. ACTs are recommended as the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum, the deadliest malaria parasite. Derived from the sweet wormwood plant (Artemisia annua), rapidly reduces the number of parasites in the bloodstream by targeting the parasite's young ring stage. The combination with a partner drug helps extend the treatment's effectiveness, prevent recurrences, and delay the development of resistance. Sing artemisinin alone can lead to the development of resistance. The partner drug in ACTs reduces this risk by targeting different stages of the parasite's life cycle. ACTs provide a more effective and durable treatment by using two drugs with distinct mechanisms of action.²⁰

Challenges in Malaria Treatment and Control:

Several challenges impede effective malaria treatment and control efforts. Drug resistance, particularly in P. falciparum, is a pressing concern that undermines the efficacy of available antimalarial drugs. The complex life cycle of Plasmodium parasites, involving different stages in both humans and mosquitoes, presents difficulties in developing interventions that effectively target all stages of the parasite's lifecycle.²¹

Socioeconomic factors, including poverty and limited access to healthcare facilities, exacerbate the malaria burden in endemic areas. Health systems in these regions often lack the necessary infrastructure and resources for timely diagnosis and treatment. Furthermore, developing safe and effective vaccines has proven elusive, challenging prevention.

The interconnectedness of these challenges underscores the need for innovative approaches to malaria treatment and control. Nanotechnology has emerged as a promising avenue to address some of these limitations, offering the potential to enhance drug delivery, diagnostics, and vaccine development. The subsequent sections of this review delve into the transformative role of nanotechnology in overcoming these challenges and advancing malaria management strategies. (Table.1)

Table 1: Advantages and disadvantages of currently available anti-malarial agents

Anti-Malarial Agent	Advantages	Disadvantages	Clinical Indications	References
Chloroquine	Cost-effective	Widespread resistance in many regions	Uncomplicated Plasmodium falciparum and Plasmodium vivax malaria	^22
Artemisinin-based	Rapid parasite clearance	Short half-life requires combination therapy	Uncomplicated malaria	^23
Combination therapy	Effective against multidrug-resistant strains	Potential for resistance development	First-line treatment in many regions	^24
Mefloquine	Long duration of action	Neuropsychiatric side effects	Prophylaxis in resistant areas	^25
Atovaquone-	Rapid onset of action	High cost and limited accessibility	Prophylaxis for travellers	^26
Proguanil	Well-tolerated in most individuals	Potential for resistance development	Combination therapy in some cases	^27
Quinine	Long history of use	Complex dosing regimen	Severe malaria	^28
Dihydroartemisinic-	Long half-life allows once-daily dosing	Potential for resistance development	Malaria prevention in travellers	^29
Piperaquine	Effective against multidrug-resistant strains	Limited availability in some regions	Second-line treatment in some regions	^30
Primaquine	Effective against hypnozoites	Risk of hemolysis in G6PD-deficient	Radical cure of P. vivax and P. ovale	^31
Chloroquine	Cost-effective	Widespread resistance in many regions	Uncomplicated Plasmodium falciparum and Plasmodium vivax malaria	^22
Piperaquine	Effective against multidrug-resistant strains	Limited availability in some regions	Second-line treatment in some regions	^30,31

Nanotechnology in Medicine:

Overview of Nanotechnology: Nanotechnology involves manipulating and engineering materials and structures at the nanoscale, typically ranging from 1 to 100 nanometers. At this scale, materials often exhibit unique properties and behaviours that differ from their bulk counterparts. Nanotechnology offers innovative solutions for drug delivery, diagnostics, imaging, and therapy in medicine. The ability to precisely design and control nanoscale structures has opened new possibilities for addressing complex medical challenges.³² (Table 2).

Nanoparticles in Drug Delivery: Nanoparticles have gained significant attention in drug delivery due to their capacity to encapsulate, protect, and deliver therapeutic agents to specific target sites within the body. By altering nanoparticles' size, composition, and surface properties, researchers can achieve controlled drug release, prolonged circulation times, and enhanced bioavailability. Various types of nanoparticles, including liposomes, polymeric nanoparticles, micelles, and dendrimers, have been explored as carriers for antimalarial drugs.³³

Nanotechnology Applications in Infectious Diseases:

Nanotechnology holds promise in combating infectious diseases, including malaria. In addition to drug delivery, nanoparticles can be utilized for various purposes, such as improving the sensitivity and specificity of diagnostic tests, enhancing vaccine efficacy, and developing novel therapeutic strategies. For instance, nano diagnostic nanoparticle tools can detect malaria parasites at low concentrations, enabling early and accurate diagnosis of disease.³⁴

Table 2: Advantages and limitations of various nanocarrier systems

Nanocarrier System	Advantages	Limitations	References
Liposomes	Biocompatible, biodegradable	Limited stability during storage	^35
Polymeric	Tailored release kinetics	Complexity in synthesis and scalability	^36
Nanoparticles	Drug loading capacity	Potential toxicity of polymers	^37
Dendrimers	Defined structure and size	Complex synthesis and high cost	^38
Nanoparticles Surface Ligands	Enhanced stability and circulation time	Complexity in formulation and scale-up	^39

Nanotechnology-Based Strategies for Malaria Control^40-44

Targeted Drug Delivery Systems:

Nanotechnology has revolutionized drug delivery systems, enabling the precise and targeted delivery of antimalarial drugs to infected cells and parasites. This section explores nanocarriers designed to enhance drug efficacy and minimize adverse effects.

Lipid-Based Nanocarriers:

Lipid-based nanocarriers, such as liposomes and lipid nanoparticles, have shown promise in delivering antimalarial drugs. These nanocarriers encapsulate hydrophobic drugs, protecting them from degradation and improving their solubility. Additionally, they can be functionalized to specifically target infected red blood cells or Plasmodium-infected tissues, increasing drug accumulation at the site of action.

Polymer-Based Nanoparticles:

Polymer-based nanoparticles offer versatility in drug delivery due to their tunable properties and biocompatibility. They can encapsulate hydrophobic and hydrophilic drugs, providing a platform for combination therapies. Polymer nanoparticles can be designed to release drugs in response to specific triggers, such as pH changes or enzyme activity, enhancing drug bioavailability and efficacy.

Nano vaccines for Malaria Prevention:

Nanotechnology-based vaccines represent a promising approach to malaria prevention. Nanoparticles can efficiently deliver antigens and adjuvants, enhancing the immune response and inducing protective immunity. This section explores using nano vaccines containing key Plasmodium antigens to stimulate robust and sustained immune reactions, potentially leading to more effective malaria vaccines.

Nano Diagnostic Tools for Malaria Detection:

Early and accurate diagnosis of malaria is crucial for timely treatment and control. Nanotechnology has facilitated the development of sensitive and rapid diagnostic tools. Nanoparticle-based diagnostic platforms can detect highly sensitive malaria-specific biomarkers, allowing for point-of-care testing in resource-limited settings. These tools offer the potential to improve case management and reduce transmission rates.

Challenges and Considerations:

Biocompatibility and Safety Concerns:

Integrating nanotechnology into malaria control strategies brings concerns regarding the biocompatibility and safety of nanomaterials. Nanoparticles used in drug delivery, vaccines, and diagnostics must undergo rigorous testing to ensure they do not induce toxicity, immune responses, or other adverse effects in the host organism. Understanding the long-term effects of nanoparticle exposure on human health and the environment is crucial to avoid unintended consequences.

Regulatory and Ethical Challenges:

Translating nanotechnology-based innovations from the laboratory to clinical applications faces regulatory and ethical hurdles. The approval processes for new drugs, vaccines, and diagnostics must address nanomaterials' unique properties and behaviours. Additionally, ethical considerations surrounding informed consent, potential risks, and benefits of nanotechnology interventions must be carefully managed, especially in vulnerable populations.

Manufacturing and Scale-Up Challenges:

The production of nanotechnology-based interventions at a scale suitable for widespread use presents manufacturing challenges. Maintaining consistent quality and reproducibility of nanoparticles can be complex and resource-intensive. Scaling up nanoparticle manufacturing while ensuring batch-to-batch consistency is essential to meet the demands of malaria-endemic regions.

Cost-Effectiveness and Accessibility:

While nanotechnology holds promise for enhancing malaria control, concerns about the cost-effectiveness and accessibility of nanotechnology-driven interventions arise. Developing and producing nanoparticles can be expensive, impacting their affordability and deployment in resource-limited settings. Strategies to optimize production processes, reduce costs, and facilitate technology transfer are essential to ensure equitable access to these innovations.

Case Studies: Successful Nanotechnology Approaches^45-46

Artemisinin-Loaded Nanoparticles:

Artemisinin, a critical antimalarial drug, faces challenges such as low solubility and rapid clearance from the bloodstream, which can limit its efficacy. Researchers have developed innovative solutions by encapsulating artemisinin within nanoparticles. These nanoparticles enhance the drug's solubility and prolong its release, leading to improved pharmacokinetics and therapeutic outcomes. This case study highlights the potential of artemisinin-loaded nanoparticles in addressing drug resistance and increasing the effectiveness of malaria treatment.

Nanoemulsion-Based Drug Delivery Systems:

Nanoemulsion are colloidal systems composed of oil, water, surfactants, and co-surfactants. They offer advantages for drug delivery, such as improved drug solubilization, stability, and bioavailability. In malaria treatment, nanoemulsion-based delivery systems have been explored to effectively encapsulate and deliver antimalarial drugs. This case study showcases how nanoemulsion can enhance drug delivery to target sites, optimize drug release profiles, and potentially reduce dosing frequency, thereby improving patient adherence to treatment regimens.

Targeted Nano vaccines for Malaria:

Nanotechnology has enabled the design of targeted nano vaccines that enhance the immune response against malaria parasites. Researchers have developed nano vaccines that mimic the natural infection by encapsulating Plasmodium antigens within nanoparticles, leading to robust and sustained immune responses. These nano vaccines offer the potential to induce protective immunity against malaria while minimizing adverse effects. This case study illustrates how targeted nano vaccines can contribute to developing effective malaria prevention strategies.

Future Directions and Emerging Trends:

Personalized Nanomedicine for Malaria:

Personalized medicine tailors’ treatments to individual patient's characteristics, optimizing therapeutic outcomes. Nanotechnology offers opportunities to create customized nanomedicine approaches for malaria. Researchers can design nanoparticles with tailored properties for optimized drug delivery, vaccine responses, and diagnostics by utilizing patient-specific data, such as genetic profiles or disease progression. Personalized nanomedicine holds the potential to increase treatment efficacy while minimizing side effects, ultimately leading to improved patient outcomes.

Combination Therapies and Synergistic Effects:

Combination therapies involving multiple drugs with complementary mechanisms of action have effectively tackled drug-resistant malaria. Nanotechnology can facilitate the controlled co-delivery of numerous antimalarial medicines within a single nanoparticle system. This approach improves patient compliance by reducing the number of doses and allows for synergistic effects between drugs. Nanotechnology-driven combination therapies have the potential to overcome drug resistance, enhance therapeutic efficacy, and prolong the lifespan of available antimalarial drugs.

Advancements in Nanomaterial Design:

As nanotechnology continues to evolve, advancements in nanomaterial design promise to enhance the performance of malaria interventions. Researchers are exploring novel materials, such as multifunctional nanoparticles and hybrid constructs, that offer improved drug loading, controlled release, and enhanced targeting. Furthermore, incorporating stimuli-responsive elements into nanomaterials allows for on-demand drug release and optimized therapeutic responses.

CONCLUSION:

This review explores the transformative potential of nanotechnology in malaria management. It delves into current challenges, pharmaceutical strategies, successful case studies, and emerging trends, highlighting nanotechnology's critical role. The findings underscore the significant impact of nanotechnology in addressing malaria treatment and control challenges. Nanoparticle-based drug delivery systems improve efficacy and reduce side effects, while nanoformulations enhance drug release profiles. Nano vaccines and diagnostics offer promising prevention and early detection solutions. These interventions collectively boost existing approaches and provide novel solutions. The successful integration of nanotechnology in malaria management serves as a model for other infectious diseases and healthcare challenges. As the field advances, collaboration among researchers, clinicians, policymakers, and industry stakeholders is crucial. Despite challenges like biocompatibility, regulation, manufacturing, and accessibility, nanotechnology's impact on patient outcomes and global health strategies is undeniable. Integrating nanotechnology in malaria treatment and control offers a promising path forward, significantly contributing to reducing malaria-related morbidity and mortality and advancing global health goals.

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

ACKNOWLEDGMENTS:

The authors would like to thank Gurunanak institutions technical campus-School of Pharmacy Hyderabad for their kind support in thise work.

REFERENCES:

1. Krushna K. Zambare, Avinash B. Thalkari, Nagesh S. Tour. A Review on Pathophysiology of Malaria: A Overview of Etiology, Life Cycle of Malarial Parasite, Clinical Signs, Diagnosis and Complications. Asian J. Res. Pharm. Sci. 2019; 9(3): 226-230. doi: 10.5958/2231-5659.2019.00035.3

2. Anil K Agarwal, Abhishek Yadav, C. P., Paromita Kuity, Jaya Mishra. Development of Antimalarial Pharmacotherapy and its importance in Malaria Treatment/Public Health Program. Asian Journal of Pharmaceutical Analysis. 2022; 12(4): 233-2. doi.org/10.52711/2231-5675.2022.00038.

3. Wells TN, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. Nature reviews Drug discovery. 2009; 8(11): 879-91.

4. Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, Price RN. Identifying and combating the impacts of COVID-19 on malaria. BMC Medicine. 2020; 18(1): 1-7. doi.org/10.1186/s12916-020-01710-x

5. Russell TL, Beebe NW, Cooper RD, Lobo NF, Burkot TR. Successful malaria elimination strategies require interventions that target changing vector behaviours. Malar J. 2013; 12(1): 56. doi: 10.1186/1475-2875-12-56.

6. Krushna K. Zambare, Avinash B. Thalkari, Nagesh S. Tour. A Review on Pathophysiology of Malaria: A Overview of Etiology, Life Cycle of Malarial Parasite, Clinical Signs, Diagnosis and Complications. Asian J. Res. Pharm. Sci. 2019; 9(3): 226-230. doi: 10.5958/2231-5659.2019.00035.3

7. Kiran Patole, Anil Danane, Amit Nikam, Anuja Patil. Review on Nanotechnology and its utilization in Pharmaceuticals. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4): 319-2. doi: 10.52711/2231-5659.2021.00050

8. Pagar Swati A., Suryawanshi Hemant K.. Nanotechnology- Finding proofs for its ancient origin. Asian J. Res. Pharm. Sci. 2021; 11(1): 65-70. doi: 10.5958/2231-5659.2021.00011.4

9. Chima RI, Goodman CA, Mills A. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy. 2003; 63(1): 17-36. doi: 10.1016/s0168-8510(02)00036-2. doi.org/10.1016/S0168-8510(02)00036-2

10. Smith T, Maire N, Ross A, Penny M, Chitnis N, Schapira A, Studer A, Genton B, Lengeler C, Tediosi F, De Savigny D. Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology. 2008; 135(13): 1507-16. doi:10.1017/S0031182008000371

11. Martens WJ, Niessen LW, Rotmans J, Jetten TH, McMichael AJ. Potential impact of global climate change on malaria risk. Environmental Health Perspectives. 1995; 103(5): 458-64. doi.org/10.1289/ehp.95103458

12. De Beaudrap P, Turyakira E, White LJ, Nabasumba C, Tumwebaze B, Muehlenbachs A, Guérin PJ, Boum Y, McGready R, Piola P. Impact of malaria during pregnancy-on-pregnancy outcomes in a Ugandan prospectivecohort with intensive malaria screening and prompt treatment. Malaria Journal. 2013; 12: 1-1. doi.org/10.1186/1475-2875-12-139

13. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low‐and middle‐income countries. Annals of the New York Academy of Sciences. 2019; 1450(1): 15-31. /doi.org/10.1111/nyas.14092

14. Mishra M, Mishra VK, Kashaw V, Iyer AK, Kashaw SK. Comprehensive review on various strategies for antimalarial drug discovery. European Journal of Medicinal Chemistry. 2017; 125: 1300-20. doi.org/10.1016/j.ejmech.2016.11.025

15. Barnes KI, White NJ. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Tropica. 2005; 94(3): 230-40. doi.org/10.1016/j.actatropica.2005.04.014

16. Greenwood D. The quinine connection. Journal of Antimicrobial Chemotherapy. 1992 ; 30(4):417-27. doi.org/10.1093/jac/30.4.417

17. Warhurst DC. Antimalarial drugs: an update. Drugs. 1987; 33: 50-65. doi.org/10.2165/00003495-198733010-00003

18. Pérez B, Teixeira C, Albuquerque IS, Gut J, Rosenthal PJ, Prudêncio M, Gomes P. PRIMACINS, N-cinnamoyl-primaquine conjugates, with improved liver-stage antimalarial activity. Med Chem Comm. 2012; 3(9): 1170-2. doi.org/10.1039/C2MD20113E

19. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, Brockman A, Villegas L, Looareesuwan S, White NJ, Nosten F. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clinical Infectious Diseases. 2002; 35(12): 1498-504. https://doi.org/ 10.1086/344901

20. Rishabh Aggarwal, Ashutosh Chamoli, Mayank Rawat, Anuj Nautiyal. A Review on Malaria, its Control and Management. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(2): 154-0. doi: 10.52711/2231-5659.2023.00027

21. Schellenberg D, Abdulla S, Roper C. Current issues for anti-malarial drugs to control P. falciparum malaria. Current Molecular Medicine. 2006; 6(2): 253-60. doi.org/10.2174/ 156652406776055168

22. Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iranian Journal of Medical Sciences. 2017; 42(2): 115.

23. Davis TM, Karunajeewa HA, Ilett KF. Artemisinin‐based combination therapies for uncomplicated malaria. Medical Journal of Australia. 2005; 182(4): 181-5.

24. Thu AM, Phyo AP, Landier J, Parker DM, Nosten FH. Combating multidrug‐resistant Plasmodium falciparum malaria. The FEBS Journal. 2017; 284(16): 2569-78. doi.org/10.1186/s12936-018-2620-y

25. Ahmad SS, Rahi M, Ranjan V, Sharma A. Mefloquine as a prophylaxis for malaria needs to be revisited. International Journal for Parasitology: Drugs and Drug Resistance. 2021 1; 17: 23-6. doi.org/10.1016/j.ijpddr.2021.06.003

26. Castelli F, Odolini S, Autino B, Foca E, Russo R. Malaria prophylaxis: a comprehensive review. Pharmaceuticals. 2010; 3(10): 3212-39. doi.org/10.3390/ph3103212

27. McKeage K, Scott LJ. Atovaquone/Proguanil: A Review of its Use for the Prophylaxis of Plasmodium. Drugs. 2003; 63: 597-623. doi.org/10.2165/00003495-200363060-00006

28. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug safety. 2004; 27: 25-61. doi.org/10.2165/00002018-200427010-00003

29. Paik IH. Orally active and robust Artemisinin-derived trioxanes: Antimalarial, antiproliferative, and anticancer efficacies. The Johns Hopkins University; 2006.

30. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Current Infectious Disease Reports. 2010; 12: 165-73. doi.org/10.1007/s11908-010-0099-y

31. Betuela I, Robinson LJ, Hetzel MW, Laman M, Siba PM, Bassat Q, Mueller I. Primaquine treatment for Plasmodium vivax-an essential tool for malaria control and elimination in Papua New Guinea. Papua New Guinea Medical Journal. 2014; 57(1/4): 68-74. doi/10.3316/informit.828705526658515

32. Sangar Omkar S., Patil Aishwarya C., Payghan Santosh A.. Nanoparticles: As a Nano based Drug Delivery System. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(1): 11-6. doi.org/10.52711/2231-5659.2022.00003

33. Priyanka Khot, Kavita Nangare, Vaishali Payghan, Tejashree Kamble, Santosh Payghan. Drug Delivery Systems Based on Polymeric Micelles. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(1): 37-1. doi: 10.52711/2231-5659.2022.00007

34. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Advanced Drug Delivery Reviews. 2010; 62(4-5): 378-93. doi.org/10.1016/j.addr.2009.11.011

35. Swarnima Pandey, Vikas Srivastava. An Overview on Invasomes: Novel Vesicular Carrier for Transdermal Drug Delivery. Research Journal of Topical and Cosmetic Sciences. 2021; 12(2): 107-2. doi: 10.52711/2321-5844.2021.00015

36. Wang WE, Zhang MJ, Chu LY. Functional polymeric microparticles engineered from controllable microfluidic emulsions. Accounts of Chemical Research. 2014; 47(2): 373-84. doi.org/10.1021/ar4001263

37. Pagar Swati A., Suryawanshi Hemant K.. Nanotechnology- Finding proofs for its ancient origin. Asian J. Res. Pharm. Sci. 2021; 11(1): 65-70. doi: 10.5958/2231-5659.2021.00011.4

38. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Advanced Drug Delivery Reviews. 2012; 64: 102-15. doi.org/10.1016/j.addr.2012.09.030

39. Abd Ellah NH, Abouelmagd SA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Expert Opinion on Drug Delivery. 2017; 14(2): 201-14. doi.org/10.1080/17425247.2016.1213238

40. Katta. Manogna, E. Nanda Krishna Reddy, T.N. Shilpa. Polymeric Novel Vesicular Drug Delivery System: An Updated Overview of Microspheres. Research J. Topical and Cosmetic Sci. 2017; 8(2): 64-72. doi: 10.5958/2321-5844.2017.00008.5

41. Rashidzadeh H, Tabatabaei Rezaei SJ, Adyani SM, Abazari M, Rahamooz Haghighi S, Abdollahi H, Ramazani A. Recent advances in targeting malaria with nanotechnology-based drug carriers. Pharmaceutical Development and Technology. 2021; 26(8): 807-23. doi.org/10.1080/10837450.2021.1948568

42. Alimardani V, Abolmaali SS, Tamaddon AM. Recent advances on nanotechnology-based strategies for prevention, diagnosis, and treatment of coronavirus infections. Journal of Nanomaterials. 2021; 1-20. doi.org/10.1155/2021/9495126

43. Kirtane AR, Verma M, Karandikar P, Furin J, Langer R, Traverso G. Nanotechnology approaches for global infectious diseases. Nature Nanotechnology. 2021; 16(4): 369-84. doi.org/10.1038/s41565-021-00866-8

44. Papaioannou I, Utzinger J, Vounatsou P. Malaria-anemia comorbidity prevalence as a measure of malaria-related deaths in sub-Saharan Africa. Scientific Reports. 2019; 9(1): 11323. doi.org/10.1038/s41598-019-47614-6

45. Ramazani A, Keramati M, Malvandi H, Danafar H, Kheiri Manjili H. Preparation and in vivo evaluation of anti-plasmodial properties of artemisinin-loaded PCL–PEG–PCL nanoparticles. Pharmaceutical Development and Technology. 2018; 23(9): 911-20. doi.org/10.1080/10837450.2017.1372781

46. Santos-Magalhães NS, Mosqueira VC. Nanotechnology applied to the treatment of malaria. Advanced Drug Delivery Reviews. 2010; 62(4-5): 560-75. doi.org/10.1016/j.addr.2009.11.024

Received on 13.09.2023         Modified on 15.01.2024

Accepted on 28.03.2024   ©Asian Pharma Press All Right Reserved

Asian J. Pharm. Res. 2024; 14(3):235-241.

DOI: 10.52711/2231-5691.2024.00037